Innovation Pharmaceuticals Inc (IPIX)

[Cognition]

What a quote from today’s PR...

“An effective broad-spectrum antiviral is largely absent in medicine today,” commented Leo Ehrlich, Chief Executive Officer at Innovation Pharmaceuticals. “So it is extremely rewarding to see Brilacidin exhibit consistent in vitro inhibition against coronaviruses and alphaviruses. These current research findings have us believe Brilacidin’s broad spectrum potential may even go farther, extending into other virus families, due to its unique properties as a defensin-mimetic. The ASV 2021 presentation provides an ideal forum for us to showcase the pre-clinical antiviral activity of Brilacidin, which we hope to see duplicated in our ongoing Phase 2 clinical trial of Brilacidin in hospitalized COVID-19 patients. If Brilacidin goes on to realize its promise as a broad spectrum antiviral, the potential benefits to patients and shareholders for this drug would likely be greater than I or anyone could have ever imagined.”